Silencing of circular RNA‑ZYG11B exerts a neuroprotective effect against retinal neurodegeneration

Int J Mol Med. 2022 Aug;50(2):106. doi: 10.3892/ijmm.2022.5162. Epub 2022 Jun 22.

Abstract

Ischemic retinal diseases are the major cause of vision impairment worldwide. Currently, there are no available treatments for ischemia‑induced retinal neurodegeneration. Circular RNAs (circRNAs) have emerged as important regulators of several biological processes and human diseases. The present study investigated the role of circRNA‑ZYG11B (circZYG11B; hsa_circ_0003739) in retinal neurodegeneration. Reverse transcription quantitative polymerase chain reaction (RT‑qPCR) demonstrated that circZYG11B expression was markedly increased during retinal neurodegeneration in vivo and in vitro. Cell Counting Kit‑8, TUNEL and caspase‑3 activity assays revealed that silencing of circZYG11B was able to protect against oxidative stress‑ or hypoxic stress‑induced retinal ganglion cell (RGC) injury. Furthermore, immunofluorescence staining and hematoxylin and eosin staining revealed that silencing of circZYG11B alleviated ischemia/reperfusion‑induced retinal neurodegeneration, as indicated by reduced RGC injury and decreased retinal reactive gliosis. In addition, luciferase reporter, biotin‑coupled miRNA capture and RNA immunoprecipitation assays revealed that circZYG11B could regulate RGC function through circZYG11B/microRNA‑620/PTEN signaling. Clinically, RT‑qPCR assays demonstrated that circZYG11B expression was markedly increased in the aqueous humor of patients with glaucoma. In conclusion, circZYG11B may be considered a promising target for the diagnosis and treatment of retinal ischemic diseases.

Keywords: circular RNA; ischemia/reperfusion; retinal ischemia; retinal neurodegeneration.

MeSH terms

  • Humans
  • Ischemia / metabolism
  • MicroRNAs* / metabolism
  • Neuroprotective Agents* / pharmacology
  • RNA, Circular / genetics
  • Retina / metabolism
  • Retinal Diseases* / metabolism

Substances

  • MIRN620 microRNA, human
  • MicroRNAs
  • Neuroprotective Agents
  • RNA, Circular

Grants and funding

The present study was generously supported by grants from the National Natural Science Foundation of China (grant no. 81470594).